Overhauled AERS II System Will Be Overseen By Bioinformatics Board
This article was originally published in The Tan Sheet
A new Bioinformatics Board will oversee FDA's program to develop an advanced Adverse Event Reporting System with the capability to analyze data and assist medical reviewers in spotting safety signals
You may also be interested in...
FDA is proposing increased drug safety funding to launch its web-accessible, second-generation Adverse Event Reporting System
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning